CDT EquityCDT -8.39%10 3-Year RORE % is -21.16 as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 1,295 Biotechnology companies, CDT Equity ranks worse than 59.85% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
CDT Equity's 3-Year RORE % for the quarter that ended in Dec. 2025 was -21.16%.
The industry rank for CDT Equity's 3-Year RORE % or its related term are showing as below:
CDT's 3-Year RORE % is ranked worse than 59.85% of 1295
companies
in the Biotechnology industry
Industry Median: -11.53
vs CDT: -21.16
CDT Equity (NAS:CDT) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
CDT Equity 3-Year RORE % Related Terms
CDT Equity 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for CDT Equity's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CDT Equity's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CDT Equity 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CDT Equity's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where CDT Equity's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
CDT Equity (CDT) has a 3-Year RORE % of -21.16 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CDT Equity and its competitors. According to the industry distribution chart, CDT Equity ranks #775 out of 1295 companies in the Biotechnology industry, placing it in the top 59.8%.
Is CDT Equity's 3-Year RORE % too high?
CDT Equity's current 3-Year RORE % is -21.16. Based on the distribution chart, CDT Equity ranks #775 out of 1295 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's 3-Year RORE % compare to CLDI and DCOY?
According to the Biotechnology industry distribution chart, CDT Equity ranks #775 out of 1295 companies for 3-Year RORE %. This places CDT Equity in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CDT Equity and its competitors. CDT Equity's current 3-Year RORE % is -21.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current 3-Year RORE % of -21.16. The current 3-Year RORE % is -21.16. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For CDT Equity (CDT), the current 3-Year RORE % is -21.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score
Get the complete analysis for CDT
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDT has been successfully added to your 
